key: cord-1013369-a7420by2
authors: Sherina, Natalia; Piralla, Antonio; Du, Likun; Wan, Hui; Kumagai-Braesch, Makiko; Andréll, Juni; Braesch-Andersen, Sten; Cassaniti, Irene; Percivalle, Elena; Sarasini, Antonella; Bergami, Federica; Di Martino, Raffaella; Colaneri, Marta; Vecchia, Marco; Sambo, Margherita; Zuccaro, Valentina; Bruno, Raffaele; Sachs, Michele; Oggionni, Tiberio; Meloni, Federica; Abolhassani, Hassan; Bertoglio, Federico; Schubert, Maren; Byrne-Steele, Miranda; Han, Jian; Hust, Michael; Xue, Yintong; Hammarström, Lennart; Baldanti, Fausto; Marcotte, Harold; Pan-Hammarström, Qiang
title: Persistence of SARS-CoV-2 specific B- and T-cell responses in convalescent COVID-19 patients 6-8 months after the infection
date: 2021-02-10
journal: Med (N Y)
DOI: 10.1016/j.medj.2021.02.001
sha: d48edb44f059aee48ca0e126f95e006bc18968b9
doc_id: 1013369
cord_uid: a7420by2

Background Monitoring the adaptive immune responses during the natural course of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection provides useful information for the development of vaccination strategies against this virus and its emerging variants. We thus profiled the serum anti-SARS-CoV-2 antibody levels and specific memory B- and T-cell responses in convalescent coronavirus disease-2019 (COVID-19) patients. Methods Altogether 119 samples from 88 convalescent donors who experienced mild to critical disease were tested for the presence of elevated anti-spike and anti-receptor binding domain antibody levels over a period of eight months. In addition, level of SARS-CoV-2 neutralizing antibodies, specific memory B- and T-cell responses were tested in a subset of samples. Findings Anti-SARS-CoV-2 antibodies were present in 85% of the samples collected within 4 weeks after onset of symptoms in COVID-19 patients. Levels of specific IgM/IgA antibodies declined after 1 month while levels of specific IgG antibodies and plasma neutralizing activities remained relatively stable up to 6 months after diagnosis. Anti-SARS-CoV-2 IgG antibodies were still present, though at a significantly lower level, in 80% of the samples collected at 6-8 months after symptom onset. SARS-CoV-2-specific memory B- and T-cell responses developed with time and were persistent in all patients followed up till 6-8 months. Conclusions Our data suggest that protective adaptive immunity following natural infection of SARS-CoV-2 might persist for at least 6-8 months, regardless of disease severity. Development of medium or long-term protective immunity through vaccination might thus be possible. Funding EU-ATAC consortium, the Italian Ministry of Health and SciLife/KAW.

have recovered from infection. [2] [3] [4] Furthermore, a large number of S protein receptor-binding domain 732 (RBD)-specific monoclonal antibodies have been isolated from convalescent patients and tested in 733 animal models 3,5,6 and clinical trials for development of potential passive immunotherapy. 7-9 It is 734 however still unclear how long the adaptive immunity to SARS-CoV-2 lasts after the natural infection 735 and furthermore, whether the antibody titer is a marker for protective immunity. A relationship 736 between a humoral immune response to SARS-CoV-2 infection and protection against reinfection has 737 been shown in rhesus macaques 10 but remains to be determined in humans. While a recent study in 738

Iceland showed that the antibody response was maintained in 90% of convalescent patients for more 739 than four months after onset of disease, 11 other studies have suggested a rapid decay of anti-SARS-740

CoV-2 IgG in individuals with mild illness. 12 

In order to evaluate the antibody response to SARS-CoV-2, 119 serum or plasma samples from 88 757 COVID-19 patients (78 from Italy and 10 from Sweden; Figure 1 , Table 1 and Table S1) Based on the symptoms presented at the time of COVID-19 diagnosis, patients were given a disease 770 score ranging from mild, moderate, severe to critical (see M&M). Analysis of anti-SARS-CoV-2 771 antibody levels did not show statistically significant differences in patients presenting with severe 772 and critical disease scores compared to mild or moderate disease groups (p=0.1444 and p=0.2943 for 773 anti-S IgG, p=0.1203 and p=0.4672 for anti-RBD IgG, respectively) ( Figures 3A-B) . Notably, in six 774 patients (11%), rather low levels or even an absence of anti-S and anti-RBD IgM, IgA and IgG 775 antibodies were observed. Sera from these individuals were obtained at median day 10.5 after 776 J o u r n a l P r e -p r o o f symptom onset (range 7-22). A second sample taken at a later time point was available for two of 777 these patients (86 and 226 days after symptom onset), where both had become anti-S and anti-RBD  778 IgG positive. For the other four samples (7%), no second sample was available for analysis. These four 779 individuals had a higher median age (79 years) compared to the entire patient cohort (62 years), had 780 severe disease scores, and two of them later died from COVID-19 complications. When patients were 781 divided based on sex, no statistically significant differences were observed in anti-S and anti-RBD 782 antibody levels for all isotypes, except for anti-RBD IgG, where significantly higher levels were 783 present in males compared to females with severe/critical disease scores (p=0.0306) ( Figures 3C-D) . 784

To examine the longevity of the anti-SARS-CoV-2 antibody response, we subsequently analyzed all 786 119 samples from the 88 patients collected at different time points (7 to 240 days after symptom 787 onset). Anti-S and anti-RBD antibody levels were significantly increased already 7 to 14 days after 788 symptom onset (p<0.0001 for all isotypes) and reached maximum at day 15 to 28 ( Figure 4 ) (days 7-789 14 to days 15-28, p=0.0087 and p=0.0309 for IgM, p=0.0080 and p=0.0029 for IgA, p=0.0159 and 790 p=0.0049 for IgG, respectively). After day 28, a significant decrease in anti-S and anti-RBD IgM and 791

IgA antibody levels was observed (days 15-28 to days 29-90, p=0.0184 for anti-RBD IgA; days 15-28 to 792 days 91-180, p<0.0001 for anti-S and anti-RBD IgM and IgA; days 15-28 to days 181-240, p<0.0001 for 793 anti-S and anti-RBD IgM and IgA). No significant decrease in anti-S and anti-RBD IgG levels was 794 present by days 91-180 (days 15-28 to days 91-180, p=0.1847 and p=0.0544, respectively), however a 795 significant decline was observed by days 181-240 (days 15-28 to days 181-240, p=0.0003 and 796 p=0.0002, respectively). Importantly, a prominent anti-SARS-CoV-2 IgG response was still present in 797 80% (12/15) of the patients who were followed 181-240 days (6-8 months) after onset of symptoms. 798

These patients had mild (n=5), moderate (n=2) and severe (n=5) disease scores at the time of 799 diagnosis. 800 801 J o u r n a l P r e -p r o o f To further evaluate the dynamics of the anti-SARS-CoV-2 antibody response, we compared the 802 antibody levels in paired samples from twenty-seven patients. The first sample (time point 1, TP1) 803 was taken at median day 21 (range 7-64) after onset of symptoms and the paired second sample 804 (TP2) was taken at median day 126 (range 57-234). This analysis showed a significant decrease in 805 anti-S IgM and IgA levels (p<0.0001 and p=0.0008, respectively), as well as in anti-RBD IgM and IgA 806 levels (p=0.0002 and p=0.0052, respectively) in the paired second samples ( Figure 5 ). No significant 807 decline in anti-S and anti-RBD IgG levels, however, was observed (p=0.1551). together, these data suggest that an anti-SARS-CoV-2 antibody response was induced in a majority of 817 COVID-19 patients in our study cohort and although IgM and IgA antibodies rapidly declined, IgG 818 antibodies and plasma neutralizing activity remained present, albeit at lower levels, for at least 6-8 819 months after diagnosis. 820 821

To address the question whether SARS-CoV-2-specific memory B and T cells were generated and how 823 long the B-and T-cell mediated responses persist in COVID-19 convalescent individuals, we analyzed 824 32 PBMC samples collected from 24 patients (mild=11, moderate=4, severe=8, critical=1, Table S1 ). approximately 2 weeks-1 month, 3-6 months and 6-8 months, respectively). No, or a negligible 829 number of B cells secreting RBD-specific IgG antibodies were detected by ELISpot (for details see 830 M&M) in samples from four healthy individuals and seven pre-pandemic buffy coats. Using the 831 highest value observed from all negative controls as a cut-off, RBD-specific IgG producing B cells were 832 detected in 33% (2/6), 93% (14/15) and 100% (11/11) of the patient samples collected at 2 weeks-1 833 month, 3-6 months and 6-8 months after onset of symptoms, respectively ( Figure 6A ). Compared to 834 the early time point samples, the number of RBD-specific IgG producing cells was significantly higher 835 in the latter time point groups (p=0.0001 and p=0.0006, for 3-6 or 6-8 months vs. 2 weeks-1 month, 836 respectively) ( Figure S2A , Table S2 ). The B cell response seemed to reach a maximum at 3-6 months 837 after infection, although there was no significant decrease observed at 6-8 months ( Figure 6B , S2A, 838 p=0.1982, Table S2 ). Furthermore, no significant difference was observed for the number of specific 839 B cells among patients with different disease scores ( Figure S3A , Table S3) in the negative controls, such T cells were observed at a level above the cut-off in 17% to 100% of 847 patient samples tested, depending on the peptide pool tested (S1, S2 N or S N M O protein-derived) 848 and in which cytokines were analyzed ( Figures 6C-E) . In two patients, a high number of IFN-γ and/or 849 IL-2 producing T cells was also detected in the control cultured without adding the SARS-CoV-2 850 peptides, which may suggest an ongoing inflammation. Overall, a T cell response against at least one 851 of the SARS-CoV-2 peptide pools was detectable in all patient (n=6) tested at the early point (2 852 weeks-1 month), and the response was maintained in the vast majority of patients analyzed at the 853 later time points (93% (14/15) and 100% (11/11) at 3-6 or 6-8 months after onset of symptoms, 854 respectively). Notably, the only patient who had no T cell response at 4 months, had a detectable 855 memory B cell response. Compared to the early time point samples, the number of S1-specific IL-2, 856 IFN-γ and IL2/IFN-γ producing T cells was significantly higher in the later time points samples, 857 especially those collected at 6-8 months after the onset of infection (p=0.0047, 0.0033 and 0.0019, 858 Table S2 ). Similar results were observed for the SNMO but not S2 peptide 859 pool specific T cells. No statistically significant differences were observed for the number of cytokine-860 producing T cells for all three peptide pools among patients with different disease scores (p>0.05, 861 Table S3 ). Taken together, while anti-RBD IgG levels decreased over time, SARS-CoV-2-862 specific T cells, in addition to specific memory B cells, were also generated and remained present in 863 the vast majority of patients followed to date, regardless of disease severity ( Figure 6F responses with antibody levels reaching a peak at 23 days following symptom onset and being 897 maintained for at least 4 months, 11,14-20 yet contradictory to others, where a low prevalence and 898 rapid decay (within 3 months) of anti-SARS-CoV-2 antibodies in COVID-19 patients with either mild 899 or severe disease were observed. 12,21 In agreement with other reports, we also observed higher anti-900 RBD IgG antibody titers in males who were more severely affected by SARS-CoV-2 infection while 901 seven percent of patients with a severe disease score in our study did not develop, or had extremely 902 low level of antibodies, suggesting that they mounted a weaker anti-viral immune response. COVID-19 cohorts, as the number of patients included, the sample collection time points, the 912 treatment used and the age and sex of study subjects could all affect the analysis. 26 Furthermore, the 913 use of negative controls and setting of cut-offs may also contribute the differences among studies. In 914

our study, we have tested patients with both mild and severe disease, using the RBD and S antigens 915 and compared the patients to historical controls (pre-pandemic samples) and set the cut-offs 916 accordingly. Under these conditions, we demonstrated that the level of anti-S and anti-RDB IgG 917 remained relatively stable, i.e., no significant decline, up to 6 months after diagnosis, regardless of 918 disease severity. Although the protective role of antibodies against SARS-CoV-2 remains uncertain, in 919 agreement with previous reports, we observed that the levels of anti-RBD antibodies correlated with 920 the plasma neutralization activity. 17,19,27 A recent study suggested that despite that the anti-RBD, S2 921 and N protein antibody levels declined over the 6-8 months period, the neutralizing titers showed an 922 insignificant decay. 28 In our study, the decline in anti-RBD and anti-S IgG antibodies observed after 6 923 months was paralleled by a corresponding decrease in neutralization titers, which is in agreement 924 with another recent report. 32 It is important to point out that in both cases, the anti-RBD antibodies 925 and plasma neutralizing activity were reduced but remained detectable 6 months after the infection. CoV-2-specific, IL-2 and/or IFN-γ producing cells are present in a vast majority of samples collected 949 from patients with disease scores ranging from mild to severe. Furthermore, we showed that specific 950 T cell responses not only were detectable but also appeared to be maintained 6-8 months after the 951 onset of disease (the longest followed up time in the literature). This is somewhat in contrast to 952 recent studies showing that the T cell response declined over the 6-8 months period in asymptomatic 953 as well as symptomatic COVID-19 patients. 20, 38 The difference could be explained by the small 954 number of samples included in our study, especially in the early disease phase, and/or the higher 955 proportion of aged and severe patients in our cohort, as SARS-CoV-2-specific T cell response might be 956 stronger and persist longer in patients with severe disease due to a higher viral load and/or longer 957 persistence of viral antigens. 20, 38 Some studies also noted that T cell responses directed against the S 958 and/or M protein of SARS-CoV-2 are present in 25-50% of unexposed healthy blood donors, 959 consistent with a high degree of potentially cross-reactive T cell immunity in the general 960 population. 2 The detection of memory S1-specific T cells marked by production of IL-2, IFN-γ and dual production 967 of those cytokines is indicative of induction of T cells with both effector and proliferative potential in 968 vivo. IFN-γ producing T cells is a hallmark of immunity against intracellular pathogens and although it 969

was not tested in our study, SARS-CoV-2-specific IFN-γ producing T cells were previously shown to be 970 of the CD4 + (Th1-like) or CD8 + cytotoxic phenotype. 2, 34 It was shown that convalescent patient donors 971 with undetectable antibodies against the S1 protein of SARS-CoV-2 had T-cell responses more 972 strongly directed against the M than the S1 protein. 40 Furthermore, a Th1-biased cellular immune 973 response of S-specific IFN-γ positive CD4 + T cells to pooled S peptides was detected in a majority of 974 monkeys vaccinated with S protein and was associated with induction of specific and neutralizing 975 anti-S antibodies. 41 Our results thus suggest that the use of S protein as an immunogen for 976 vaccination has the potential to induce memory T and B cell specific for the S protein and RBD in 977 humans. 978 979 Importantly, although serum IgG antibody levels decreased over time in our study, specific memory B 980 and T cells were maintained over the 6-8 months period and could potentially contribute to 981 protection from SARS-CoV-2 reinfection. 29,31 However, the detection of antibodies to SARS-CoV-2, 982 including neutralizing antibodies, as well as memory B cell and T cell over a long period does not 983 necessarily indicate protective and long-term immunity, and a correlate of protection still needs to 984 be established. Studies on common human coronaviruses show that neutralizing antibodies are 985 induced and a recent report showed that the duration of protective immunity against common cold 986 coronavirus may last 6 to 12 months. 42 Reinfections with all seasonal coronaviruses usually occur 987 within three years, 22 Mann-Whitney U test. **p≤ 0.01, *** p≤0.001, **** p≤0.0001. See also Figures S2, S3 and S4 , and 1102 Table 1 

Insights into SARS-CoV-2 genome, structure, evolution, 1250 pathogenesis and therapies: Structural genomics approach

Targets of T cell responses to SARS-CoV-2 1254 coronavirus in humans with COVID-19 disease and unexposed individuals

Humoral and circulating follicular helper T cell responses 1258 in recovered patients with COVID-19

Convergent antibody responses to SARS-CoV-2 in 1261 convalescent individuals

A SARS-CoV-2 infection model in mice 1264 demonstrates protection by neutralizing antibodies

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection 1267 from disease in a small animal model

COVID-19 antibodies on trial

SARS-CoV-2 Neutralizing antibody LY-CoV555 in outpatients with 1271 Covid-19

Development of passive immunity against SARS-CoV-2 for management of immunodeficient 1274 patients-a perspective

SARS-CoV-2 infection protects against rechallenge 1277 in rhesus macaques

Humoral immune 1280 response to SARS-CoV-2 in Iceland

Rapid decay of anti-SARS-CoV-2 1283 antibodies in persons with mild Covid-19

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Loss of anti-SARS-CoV-2 antibodies in mild 1288 covid-19

Persistence and decay of human antibody 1291 responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

Persistence of serum and saliva antibody responses to SARS-CoV-2 spike 1295 antigens in COVID-19 patients

Robust neutralizing antibodies to SARS-CoV-2 1298 infection persist for months

Rapid generation of durable B cell memory to 1301 SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence

Defining the features and duration of antibody responses to 1305 SARS-CoV-2 infection associated with disease severity and outcome

Immunological memory to SARS-CoV-2 assessed for up to 8 months 1308 after infection

Loss of anti-SARS-CoV-2 antibodies in mild covid-1310 19

A systematic review 1313 of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and 1314 association with severity

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang 1317 province, China

Autoantibodies against type I IFNs in patients 1320 with life-threatening COVID-19

Inborn errors of type I IFN immunity in patients with life-1323 threatening COVID-19

Loss of anti-SARS-CoV-2 antibodies in mild covid-19

The receptor binding domain of the viral spike 1328 protein is an immunodominant and highly specific target

SARS-CoV-2 infection elicits a rapid neutralizing antibody response 1333 that correlates with disease severity

Functional SARS-CoV-2-specific 1336 immune memory persists after mild COVID-19

SARS-CoV-2 specific memory B cells frequency in recovered patient remains stable 1339 while antibodies decay over time

Evolution of immunity to SARS-CoV-2. medRxiv

Evolution of antibody immunity to SARS-1345

Adaptive immune responses to SARS-CoV-2 infection in severe versus mild individuals. Signal

Robust T cell immunity in 1351 convalescent individuals with asymptomatic or mild COVID-19

SARS-CoV-2-reactive T cells in healthy donors and patients 1354 with COVID-19

Robust SARS-CoV-2-specific T-cell immunity is maintained at 6 1357 months following primary infection

Persistent cellular immunity to SARS-CoV-1360

Highly functional virus-specific cellular immune 1363 response in asymptomatic SARS-CoV-2 infection. bioRxiv

SARS-CoV-2-derived peptides define heterologous and COVID-1367 19-induced T cell recognition

Cellular Immunity in COVID-19 convalescents 1370 with PCR-confirmed infection but with undetectable SARS-CoV-2-specific IgG

DNA vaccine protection against SARS-CoV-2 in 1374 rhesus macaques

Seasonal coronavirus protective immunity is 1377 short-lasting

The time course of the immune 1379 response to experimental coronavirus infection of man

Fast-spreading COVID variant can elude immune responses

Broad and strong memory CD4 + and CD8 + T cells induced by SARS-CoV-2 in 1384 UK convalescent individuals following COVID-19

Detection of 2019 novel coronavirus (2019-nCoV) by 1387 real-time RT-PCR

A serological assay to detect

CoV-2 seroconversion in humans

Identifying parameters to improve the reproducibility of transient gene 1393 expression in High Five cells

SARS-CoV-2 neutralizing human recombinant 1396 antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface

Prevalence of SARS-CoV-2 specific neutralising 1400 antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06

Clinical and analytical performance of an automated 1404 serological test that identifies S1/S2-neutralizing IgG in COVID-19 patients semiquantitatively

Optimization of a human IgG B-cell ELISpot assay for the analysis of vaccine-induced B-cell 1408 responses

Preliminary identification of potential 1410 vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological 1411 studies

RBD-His protein was expressed in Expi293 cells and purified on Ni-NTA resin (#88221, Thermo Fisher) 1167 followed by size-exclusion chromatography on a Superdex 200 gel filtration column in PBS. 47 S1-S2-1168His (referred as S) protein was expressed baculovirus-free in High Five insect cells 48